Healthcare / BiotechnologyNasdaqCM
$0.69
-0.07 (-9.45%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-7.6M · quality 65.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$2M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-52.9%
↓Gross Margin
N/A
•Debt/Equity
0.38
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-8.9M · FCF $-7.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | — | — | — | $1.2M | $1.8M | $1.3M |
| Net Income | $-8.9M | $-8.9M | $-5.7M | $-8.2M | $-10.1M | $-8.5M |
| EBITDA | $-7.8M | $-7.8M | $-4.1M | $-8.1M | $-9.9M | — |
| EPS | -7.84 | -7.84 | -19.68 | -176.80 | -1768.00 | -4131.00 |
| Gross Margin | — | — | — | 24.4% | 16.3% | -3.0% |
| Operating Margin | — | — | — | -701.1% | -548.8% | -448.1% |
| Net Margin | — | — | — | -701.0% | -548.7% | -675.7% |
| Balance Sheet | ||||||
| Debt/Equity | 0.38 | 0.38 | — | 0.10 | 0.15 | — |
| Current Ratio | 20.13 | 20.13 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-7.6M | $-7.6M | $-5.7M | $-8.6M | $-8.9M | — |
| Returns | ||||||
| ROE | -52.9% | -52.9% | -223.1% | -230.3% | -278.1% | -64.0% |
| Valuation | ||||||
| P/B | 0.05 | 0.05 | 0.68 | 0.39 | 1.91 | — |
| Growth & Yield | ||||||
| Revenue Growth | — | — | — | -36.1% | — | — |
| EPS Growth | 60.2% | 60.2% | 88.9% | 90.0% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-83.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-19.68 → -7.84
Residual
-83.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.